Revolution Medicines, Inc. (RVMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Company Overview - Revolution Medicines aims to revolutionize treatment for patients with RAS-addicted cancers through innovative targeted medicines [3] - The company is a late-stage clinical oncology firm focusing on pancreatic, non-small cell lung, and colorectal cancers [4] Clinical Development - Revolution Medicines has 4 RAS(ON) inhibitors currently in clinical trials and a robust pipeline of additional candidates [4] - There are 8 ongoing or announced registrational Phase III trials, with extensive clinical experience involving over 2,500 patients [5]